ILYANG PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,710 KRW | +0.22% |
|
-1.01% | -12.40% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 499,551 | 410,527 | 1,197,901 | 510,655 | 349,981 | 281,258 |
| Enterprise Value (EV) 1 | 615,971 | 503,198 | 1,259,330 | 530,663 | 370,680 | 346,607 |
| P/E ratio | -102 x | 41.1 x | 110 x | 35.5 x | 18.7 x | -112 x |
| Yield | - | 0.53% | 0.18% | 0.71% | 0.78% | 0.96% |
| Capitalization / Revenue | 1.66 x | 1.26 x | 3.49 x | 1.38 x | 0.91 x | 0.76 x |
| EV / Revenue | 2.05 x | 1.55 x | 3.67 x | 1.43 x | 0.97 x | 0.94 x |
| EV / EBITDA | 21.4 x | 11.8 x | 26.9 x | 9.89 x | 6.93 x | 9.02 x |
| EV / FCF | 28 x | 22.4 x | 48.7 x | 12.4 x | 195 x | 81.9 x |
| FCF Yield | 3.58% | 4.47% | 2.05% | 8.07% | 0.51% | 1.22% |
| Price to Book | 2.69 x | 2.1 x | 5.81 x | 2.29 x | 1.5 x | 1.25 x |
| Nbr of stocks (in thousands) | 18,166 | 18,205 | 18,205 | 18,205 | 18,087 | 17,972 |
| Reference price 2 | 27,500 | 22,550 | 65,800 | 28,050 | 19,350 | 15,650 |
| Announcement Date | 3/14/19 | 3/4/20 | 3/11/21 | 3/10/22 | 3/16/23 | 3/7/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 300,036 | 324,573 | 343,329 | 371,348 | 383,811 | 370,537 |
| EBITDA 1 | 28,741 | 42,601 | 46,765 | 53,675 | 53,472 | 38,417 |
| EBIT 1 | 16,722 | 32,511 | 34,101 | 41,025 | 40,408 | 24,813 |
| Operating Margin | 5.57% | 10.02% | 9.93% | 11.05% | 10.53% | 6.7% |
| Earnings before Tax (EBT) 1 | 8,069 | 27,661 | 28,393 | 38,927 | 41,331 | 3,048 |
| Net income 1 | -4,893 | 9,985 | 10,880 | 14,384 | 19,238 | -2,546 |
| Net margin | -1.63% | 3.08% | 3.17% | 3.87% | 5.01% | -0.69% |
| EPS 2 | -269.4 | 548.0 | 597.0 | 790.0 | 1,036 | -140.0 |
| Free Cash Flow 1 | 22,030 | 22,484 | 25,857 | 42,832 | 1,905 | 4,233 |
| FCF margin | 7.34% | 6.93% | 7.53% | 11.53% | 0.5% | 1.14% |
| FCF Conversion (EBITDA) | 76.65% | 52.78% | 55.29% | 79.8% | 3.56% | 11.02% |
| FCF Conversion (Net income) | - | 225.18% | 237.67% | 297.78% | 9.9% | - |
| Dividend per Share | - | 120.0 | 120.0 | 200.0 | 150.0 | 150.0 |
| Announcement Date | 3/14/19 | 3/4/20 | 3/11/21 | 3/10/22 | 3/16/23 | 3/7/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 116,420 | 92,671 | 61,429 | 20,007 | 20,699 | 65,349 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 4.051 x | 2.175 x | 1.314 x | 0.3727 x | 0.3871 x | 1.701 x |
| Free Cash Flow 1 | 22,030 | 22,484 | 25,857 | 42,832 | 1,905 | 4,233 |
| ROE (net income / shareholders' equity) | 1.54% | 9.06% | 9.21% | 10% | 11.3% | 0.04% |
| ROA (Net income/ Total Assets) | 2.41% | 4.67% | 4.86% | 5.49% | 5.09% | 3.24% |
| Assets 1 | -203,343 | 213,691 | 223,731 | 261,808 | 378,008 | -78,610 |
| Book Value Per Share 2 | 10,237 | 10,754 | 11,320 | 12,249 | 12,912 | 12,567 |
| Cash Flow per Share 2 | 1,220 | 1,972 | 2,271 | 2,622 | 3,295 | 528.0 |
| Capex 1 | 1,547 | 2,174 | 10,174 | 12,911 | 4,082 | 6,089 |
| Capex / Sales | 0.52% | 0.67% | 2.96% | 3.48% | 1.06% | 1.64% |
| Announcement Date | 3/14/19 | 3/4/20 | 3/11/21 | 3/10/22 | 3/16/23 | 3/7/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -12.40% | 179M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A007570 Stock
- Financials Ilyang Pharmaceutical Co.,Ltd
